Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-3911

Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells

E-Numbers
E-251-2012-0
E-251-2012-1
E-251-2012-2
E-251-2012-3
Lead Inventors
Bharti, Kapil
Co-Inventors
Bharti, Kapil
Davis, Janine
Miller, Sheldon
Maminishkis, Arvydas
Ferrer-Alegre, Marc
Applications
Research Materials
Therapeutic Areas
Ophthalmology
Development Stages
Discovery
Lead IC
NEI
ICs
NINDS
NEI
NCATS

The retinal pigment epithelial cells (RPE) make up a polarized monolayer in the vertebrate eye that separates the neural retina from the choroid, and performs a crucial role in retinal physiology by forming a blood-retinal barrier and closely interacting with photoreceptors to maintain visual function.  Many ophthalmic diseases, such as age-related macular degeneration, are associated with a degeneration or deterioration of the RPE. 

Researchers at NEI have developed high efficiency methods for producing retinal pigment epithelial cells (RPE) from induced pluripotent stem cells (iPSCs).  The iPSCs are produced from somatic cells, including retinal pigment epithelial cells, such as fetal RPE.  These methods involve producing embryoid bodies from human iPSCs, culturing the embryoid bodies using specific media to induce differentiation into RPE and growing the differentiated RPE cells in a defined media to generate human RPE cells.  The investigators also developed methods for detecting RPE cells and authenticating RPE cells; determining agents that can affect the production of RPE cells from an iPSC; and identifying an agent that can increase RPE survival in response to a proteo toxic insult or stress.  These novel methods and RPE cells can be useful for both pre-clinical and clinical studies involving RPE.

Competitive Advantages:

  • These methods dramatically increase the efficiency of iPSC differentiation into RPE and produce superior quality RPE
  • The RPE cells produced using these methods are fully authenticated
  • These novel methods provide ways to perform high throughput screens with RPE cells

Commercial Applications:

  • Production of RPE cells for use in screening for novel ocular therapeutics and for identifying toxic side effects of drugs
  • The RPE cells produced with these methods could be used in novel cell-based therapies
  • In a research setting, these cells could be used to study the pathophysiology of RPE
Licensing Contacts
Fenn, Edward (Tedd)
tedd.fenn@nih.gov